Shire Mexico – Dr. Raul Vivar, Head of Mexico / Central America and…
The general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020…
As one of the world’s leading specialty biopharmaceutical companies, Shire has emerged as a company fully focused on a single purpose: to enable people with life-altering conditions to lead better lives. Today Shire provides treatments in the areas of Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine. The company has a portfolio of specialist therapies marketed in over 50 countries worldwide and offices in 29 countries. The company has been present in Mexico since 2008 focusing on lysosomal storage diseases therapies. In the near future the company plans to provide a therapeutic option to patients with hereditary angioedema and start its neuroscience business unit with a product indicated for ADHD (attention deficit hyperactivity disorder).
Address:
Shire Pharmaceuticals Mexico S.A. de C.V Av. Paseo de los Tamarindos 90, Torre 1, Piso 7 Col. Bosques de las Lomas, Del. Cuajimalpa C.P. 05120, México DF MEXICO Tel: +52 (55) 5081 0120 Website: www.shire.com.mxThe general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020…
A compilation of the top 10 pharmaceutical companies in the Mexican pharmaceutical market based on IQVIA data from February MAT 2020. Four of the top ten companies are Mexican: PISA,…
UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region…
Americo Garcia oversees Latin American operations for Canadian generics player Apotex. He outlines the firm’s impressive growth in the region in recent years – expanding both in terms of portfolio…
Inosan Biopharma General Manager Juan Lopez de Silanes outlines the Mexican family company’s recent milestones, including an impressive internationalisation push in the Middle East & Africa Region, how demand for…
Sara Montero, managing director of Lundbeck Mexico, Central America and Andean countries since January 2020, explains her key priorities and the importance of the region for Lundbeck, highlights the current…
Mauricio Guizar, newly appointed general manager of Ipsen Mexico since October 2019, shares his first impression of the French specialty care player’s operations in Mexico, the significance of being the…
Francisco Kuri Breña, director of new developments at local Mexican player Landsteiner, shares the company’s existing positioning as one of the top 10 suppliers of generic medicines to the Mexican…
CP Maria del Socorro España Lomeli, executive director of the Mexican generics industry association ANAFAM, discusses the challenges with regard to the ‘new rules of the game’ in Mexico’s healthcare…
Arturo Prida Romero, the president of the current National Council of the Partido de la Revolución Democrática (PRD) – one of the main political parties in Mexico – shares the…
Mario Muniz, SVP and GM of IQVIA North LATAM, shares his motivations for joining IQVIA after nearly two decades with pharma and medtech companies, the huge potential of the North…
Earlier in 2020, PharmaBoardroom sat down with several key stakeholders in the Mexican healthcare and life sciences industry, from the leaders of multinational affiliates, start-up entrepreneurs, association heads, and key…
Diego Ruiz, CEO and co-founder of Eseotr3s Pharma shares his entrepreneurial background and the motivation for establishing Eseotr3s Pharma; their focus on flexibility and quality; their international operations and network,…
See our Cookie Privacy Policy Here